Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

SABCS 2009

9 - 13 Sep 2009
Videos
Typical course for receptor positive early breast cancer
Dr Kimberly Blackwell - Duke University Medical Centre, USA
Typical course for receptor positive early breast cancer ( Dr Kimberly Blackwell - Duke University Medical Centre, USA )
9 Feb 2010
Bisphosphonates for breast cancer patients
Prof Michael Gnant - Medical University of Vienna, Austria
Bisphosphonates for breast cancer patients ( Prof Michael Gnant - Medical University of Vienna, Austria )
9 Feb 2010
Oral bisphosphonate and breast cancer: prospective results from the Women's...
Dr Rowan Chlebowski - Harbor-University of California, Los Angeles
Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI) ( Dr Rowan Chlebowski - Harbor-University of California, Los Angeles )
28 Jan 2010
Exemestane vs tamoxifen followed by exemestane
Dr Daniel Rea - University of Birmingham, UK
Exemestane vs tamoxifen followed by exemestane ( Dr Daniel Rea - University of Birmingham, UK )
28 Jan 2010
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally...
Dr David Miles - Mount Vernon Hospital, United Kingdom
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer ( Dr David Miles - Mount Vernon Hospital, United Kingdom )
28 Jan 2010
Bevacizumab in combination with chemotherapy for second-line treatment of HER2...
Prof Adam Brufsky - University of Pittsburgh Cancer Institute, USA
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer ( Prof Adam Brufsky - University of Pittsburgh Cancer Institute, USA )
28 Jan 2010
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast...
Dr Kimberly Blackwell - Duke University Medical Center, USA
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, USA )
28 Jan 2010
A novel strategy in treating endocrine resistance using combination therapy
Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San...
A novel strategy in treating endocrine resistance using combination therapy ( Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San Antonio, USA )
28 Jan 2010
Sorafenib in combination with paclitaxel for locally recurrent or metastatic...
Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA
Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer ( Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA )
28 Jan 2010
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor...
Dr Angelo Di Leo - Hospital of Prato, Italy
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Italy )
28 Jan 2010
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase...
Prof Jenny Chang - Baylor College of Medicine, USA
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors ( Prof Jenny Chang - Baylor College of Medicine, USA )
28 Jan 2010
Short term biological effects of the combination of letrozole and zoledronic...
Prof Nigel Bundred - University of Manchester, UK
Short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer ( Prof Nigel Bundred - University of Manchester, UK )
28 Jan 2010
Denosumab versus zoledronic acid for skeletal-related events in breast cancer...
Dr Alison Stopeck - University of Arizona Cancer Center
Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases ( Dr Alison Stopeck - University of Arizona Cancer Center )
28 Jan 2010
Use of bisphosphonates and risk of postmenopausal breast cancer
Dr Gad Rennert - Technion-Israel Institute of Technology, Israel
Use of bisphosphonates and risk of postmenopausal breast cancer ( Dr Gad Rennert - Technion-Israel Institute of Technology, Israel )
28 Jan 2010
Translation of endocrine systemic treatment
Prof Giuseppe Viale - European Institute of Oncology, Milan, Italy
Translation of endocrine systemic treatment ( Prof Giuseppe Viale - European Institute of Oncology, Milan, Italy )
27 Jan 2010
Using biology of tumours to predict effective therapies
Dr Laura Van`t Veer - The Netherlands Cancer Institute, Amsterdam, The...
Using biology of tumours to predict effective therapies ( Dr Laura Van`t Veer - The Netherlands Cancer Institute, Amsterdam, The Netherlands )
27 Jan 2010
Optimal way to use herceptin with adjuvant therapy
Prof Edith Perez - Mayo Clinic, Florida, USA
Optimal way to use herceptin with adjuvant therapy ( Prof Edith Perez - Mayo Clinic, Florida, USA )
27 Jan 2010
Cancer and the bone micro-environment
Prof Theresa Guise - Indiana University School of Medicine, USA
Cancer and the bone micro-environment ( Prof Theresa Guise - Indiana University School of Medicine, USA )
27 Jan 2010
Emerging approaches to clinical trial design
Susan Hilsenbeck - Baylor College of Medicine, Houston, USA
Emerging approaches to clinical trial design ( Susan Hilsenbeck - Baylor College of Medicine, Houston, USA )
27 Jan 2010
Evaluating strategies for endocrine therapy
Dr Meredith Regan - Dana-Farber Cancer Institute, Boston, USA
Evaluating strategies for endocrine therapy ( Dr Meredith Regan - Dana-Farber Cancer Institute, Boston, USA )
27 Jan 2010
How life style factors effect survival of breast cancer patients
Prof Michelle Holmes - Harvard Medical School, USA
How life style factors effect survival of breast cancer patients ( Prof Michelle Holmes - Harvard Medical School, USA )
27 Jan 2010
Fulvestrant as treatment for advanced breast cancer
Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital...
Fulvestrant as treatment for advanced breast cancer ( Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital, Italy )
27 Jan 2010
Sentinel lymph node biopsy
Prof Quentin Pankhurst and Dr Michael Douek - University College London, UK
Sentinel lymph node biopsy ( Prof Quentin Pankhurst and Dr Michael Douek - University College London, UK )
27 Jan 2010
Applying new proteomic technologies to improve patient management
Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA
Applying new proteomic technologies to improve patient management ( Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA )
27 Jan 2010
Causes and prevention of breast cancer
Dr Valerie Beral - University of Oxford, UK
Causes and prevention of breast cancer ( Dr Valerie Beral - University of Oxford, UK )
27 Jan 2010
Early breast cancer trials
Prof Sarah Darby - Clinical Trial Service Unit, Oxford University, UK
Early breast cancer trials ( Prof Sarah Darby - Clinical Trial Service Unit, Oxford University, UK )
27 Jan 2010
New paradigms in tumour immunotherapy
Dr Tyler Curiel - University of Texas Health Science Center, San Antonio, USA
New paradigms in tumour immunotherapy ( Dr Tyler Curiel - University of Texas Health Science Center, San Antonio, USA )
27 Jan 2010
San Antonio Breast Cancer Symposium, 9th-13th December 2009
Prof Gordon McVie - European Institute of Oncology, Milan
San Antonio Breast Cancer Symposium, 9th-13th December 2009 ( Prof Gordon McVie - European Institute of Oncology, Milan )
13 Jan 2010

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation